Northern Trust Corp Grows Stock Position in Haleon plc (NYSE:HLN)

Northern Trust Corp lifted its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 27.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,412,542 shares of the company's stock after buying an additional 1,172,931 shares during the quarter. Northern Trust Corp owned about 0.12% of Haleon worth $51,636,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Sierra Ocean LLC acquired a new position in Haleon during the 4th quarter worth approximately $26,000. Geneos Wealth Management Inc. bought a new stake in Haleon during the fourth quarter worth $35,000. Spire Wealth Management purchased a new position in shares of Haleon in the 4th quarter worth about $39,000. FIL Ltd grew its position in shares of Haleon by 45.7% during the 4th quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after acquiring an additional 1,270 shares during the period. Finally, Addison Advisors LLC increased its position in Haleon by 28.7% in the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after buying an additional 1,106 shares during the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Price Performance

Haleon stock traded up $0.18 during midday trading on Friday, hitting $10.75. 17,704,934 shares of the company's stock were exchanged, compared to its average volume of 7,756,341. The stock has a 50-day moving average price of $10.20 and a two-hundred day moving average price of $9.84. Haleon plc has a 52-week low of $8.24 and a 52-week high of $10.85. The company has a market cap of $48.48 billion, a P/E ratio of 31.62, a PEG ratio of 2.82 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Haleon (NYSE:HLN - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.38 billion. On average, equities research analysts forecast that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The company also recently declared a -- dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. The ex-dividend date of this dividend is Friday, April 25th. This represents a yield of 1.6%. This is a positive change from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is 58.97%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Hsbc Global Res lowered shares of Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Morgan Stanley upgraded Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price for the company in a research note on Friday. Finally, HSBC reiterated a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Five equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $11.25.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.